Stent thrombosis in a clopidogrel nonresponder

Area of Science:

• Cardiology
• Pharmacology

Background:

• Percutaneous coronary intervention (PCI) is a common procedure for coronary artery disease.
• Dual antiplatelet therapy (DAPT) is the standard of care post-PCI to prevent thrombotic events.
• Variability in patient response to antiplatelet medications like clopidogrel is increasingly recognized.

Observation:

• This case study focuses on a patient experiencing recurrent stent thrombosis.
• The patient exhibited a non-responsive platelet reaction to standard clopidogrel therapy.
• Despite conventional pharmacological management, the patient continued to have thrombotic events.

Findings:

• Clopidogrel non-responsiveness poses a significant risk for stent thrombosis.
• Standard DAPT may be insufficient for patients with suboptimal platelet inhibition.
• Personalized antiplatelet therapy strategies may be necessary for high-risk individuals.

Implications:

• This case underscores the importance of assessing platelet response to antiplatelet drugs post-PCI.
• Identifying clopidogrel non-responders is crucial for preventing recurrent stent thrombosis.
• Tailoring antiplatelet therapy based on individual patient response can improve outcomes after PCI.